A more recent study from 2014 presented additional findings regarding the 225-NP treatment of EGFR-positive lung cancer, indicating that tumoral cells are being arrested in the G2/M phase of the cell cycle and suffer DNA damage, leading to effective tumor growth inhibition both in vitro and in vivo [139]. The gene discussed is EGFR; the disease is lung cancer.